Ginkgo Bioworks

From Wikipedia, the free encyclopedia
Ginkgo Bioworks
TypePublic
NYSEDNA
IndustryBiotechnology
Founded2009; 13 years ago (2009) in Boston, Massachusetts, United States
FoundersTom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che
Headquarters,
Key people
Tom Knight
Jason Kelly
Reshma Shetty
Barry Canton
Austin Che
Christina Agapakis
Number of employees
~600
Websiteginkgobioworks.com

Ginkgo Bioworks is a biotech company from the United States founded in 2009 by scientists from MIT and headed by Tom Knight. The company specializes in using genetic engineering to produce bacteria with industrial applications.[1][2][3][4] Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and is one of the world's largest privately held biotech companies.[5] In 2019, Gingko was valued at $4.2 billion[6] and raised $290 million in September and $350 million in October of that year.[5]

On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.[7] On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be DNA. The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche.[8] Trading began September 17, 2021.[9][10]

See also[]

References[]

  1. ^ Molteni, Megan (14 September 2017). "With Designer Bacteria, Crops One Day Could Fertilize Themselves". Wired. Retrieved 4 December 2017.
  2. ^ Herper, Mathew (8 June 2016). "Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry". Forbes. Retrieved 4 December 2017.
  3. ^ Adams, Susan (14 September 2017). "Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer". Forbes. Retrieved 4 December 2017.
  4. ^ Weisman, Robert (29 September 2016). "Ginkgo Bioworks opens production site for custom cells". Boston Globe. Retrieved 4 December 2017.
  5. ^ a b "Ginkgo Bioworks raises $350 million fund for biotech spinouts". Reuters. 2019-10-09. Retrieved 2019-11-07.
  6. ^ "Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods". Bloomberg. Retrieved 2019-11-07.
  7. ^ Hussain, Niket Nishant, Noor Zainab (2021-05-11). "Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal". Reuters. Retrieved 2021-05-12.
  8. ^ Ginkgo Bioworks, Austin, Barry, Jason, Reshma, and Tom. "Taking Ginkgo Public on NYSE:DNA". Ginkgo Bioworks. Ginkgo Bioworks. Retrieved 15 May 2021.
  9. ^ Leon, Riley (17 September 2021). "Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger". CNBC. Retrieved 17 September 2021.
  10. ^ "Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds" (Press release). Business Wire. September 14, 2021.

External links[]


Retrieved from ""